Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke

• Published in: Future cardiology Vol. 14; no. 3s; pp. 31 - 37
• Main Authors: Cerezo-Manchado, Juan José, Navarro-Almenzar, Begoña, Ruiz, Ginés Elvira, García-Candel, Faustino, Blanco, Pedro Flores, Caro-Martínez, Cesar, Manzano-Fernández, Sergio, García-Iniesta, Natalia, Sánchez-García, Javier, Cabañas-Perianes, Valentín, Jiménez, José María Moraleda
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-05-2018
• Subjects: Aged; Aged, 80 and over; Anticoagulants; atrial fibrillation; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Cardiac arrhythmia; Clinical medicine; clinical practice; Clinical trials; effectiveness; Embolisms; Factor Xa Inhibitors - therapeutic use; Female; Heart; Hemorrhage - epidemiology; Humans; Male; Practice Patterns, Physicians; Prevention; Primary care; Retrospective Studies; rivaroxaban; Rivaroxaban - therapeutic use; safety; Spain; Statistical analysis; Stroke; Stroke - etiology; Stroke - prevention & control; Tertiary Care Centers; Thromboembolism; Thromboembolism - epidemiology; Spain; effectiveness; clinical practice; atrial fibrillation; rivaroxaban; safety
• ISSN: 1479-6678; 1744-8298
• DOI: 10.2217/fca-2018-0024

To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice.
Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain.
A total of 142 patients (median age 78 years, 40.1% men, 32.4% creatinine clearance <50 ml/min; 96.5% CHA
DS
-VASc ≥2; 44.3% HAS-BLED ≥3) were included. Only two patients had a thromboembolic event (in both cases ischemic stroke) and three patients had major bleeding (rates of 1.3 and 1.9 events/100 patient years, respectively).
Data regarding effectiveness and safety in our cohort were consistent with previous studies, showing that rivaroxaban can be effective and safely used in our setting.